New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
The orphan drug designation by the EC is issued for drugs which are intended to treat diseases that affect fewer than five in 10,000 people in the European Union
Approval based on a separate phase III trial among Chinese patients reinforcing mepolizumab’s efficacy and safety data
Subscribe To Our Newsletter & Stay Updated
